The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Best practices in preventing heartbreak:

A look at a SWOG cancer control trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The development of more effective cancer treatment has yielded higher cure rates, longer survival, and a decrease in cancer recurrence. As of January 2019, the National Cancer Institute estimated that there were 16.9 million cancer survivors in the United States. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Justin Floyd, DO, FACOI
Medical oncologist, Cancer Care Specialists of Illinois, Heartland NCORP
Monika Leja, MD
Clinical assistant professor, Frankel Cardiovascular Center, University of Michigan
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Ruxolitinib improves CML’s response to standard TKI treatment

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...

Byline
Justin Floyd, DO, FACOI
Medical oncologist, Cancer Care Specialists of Illinois, Heartland NCORP
Monika Leja, MD
Clinical assistant professor, Frankel Cardiovascular Center, University of Michigan
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account